ESMO is working to improve the availability of anticancer medicines and technologies in Europe and worldwide
The availability of cancer medicines is crucial for medical oncologists to be able to treat patients according to the evidence-based ESMO Clinical Practice Guidelines.
Access to high-quality, effective, and affordable cancer medicines and technologies is essential for delivering optimal care to patients worldwide. However, disparities in availability and affordability continue to pose significant challenges.
ESMO has conducted several studies to gather data on the accessibility and affordability of antineoplastic medicines, biomolecular technologies and opioids.
Discover them below
- ESMO Studies on the Availability, Out-of-Pocket Costs and Accessibility of Antineoplastic Medicines. Read more
- ESMO Study on Availability and Accessibility to Biomolecular Technologies in Oncology in Europe. Read more
- Formulary Availability and Regulatory Barriers to Accessibility to Legitimate Medical Use of Opioids for Cancer Pain. Read more